Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
NCT05287451

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Led by M.D. Anderson Cancer Center · Updated on 2026-04-15

100

Participants Needed

9

Research Sites

241 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

CONDITIONS

Official Title

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Premenopausal women with a documented harmful mutation in BRCA1, BRCA2, BRIP1, RAD51C, PALB2, or RAD51D genes
  • Age 25 to 40 years for BRCA1 mutation carriers
  • Age 25 to 45 years for BRCA2 mutation carriers
  • Age 30 to 50 years for BRIP1, RAD51C, RAD51D, and PALB2 mutation carriers
  • No longer need fallopian tubes for natural childbearing; future plans for IVF allowed
  • Have at least one fallopian tube present
  • May have a personal history of non-ovarian cancer
  • Able to provide informed consent
Not Eligible

You will not qualify if you...

  • Postmenopausal status, natural or due to cancer treatment
  • Plan to have risk-reducing oophorectomy within two years after salpingectomy, if known at enrollment
  • Legally incapable of giving consent
  • Previous bilateral salpingectomy
  • Personal history of ovarian, fallopian tube, or peritoneal cancer
  • Current signs, diagnosis, or treatment for cancer (except use of Aromatase Inhibitors, Tamoxifen, or Selective Estrogen Receptor Modulators are allowed)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 9 locations

1

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Actively Recruiting

2

Mayo Clinic

Rochester, Minnesota, United States, 55905

Actively Recruiting

3

WU St Louis

St Louis, Missouri, United States, 63130

Actively Recruiting

4

Mount Sinai Health System

New York, New York, United States, 10029

Actively Recruiting

5

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Actively Recruiting

6

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

7

Lyndon Baines Johnson General

Houston, Texas, United States, 77026

Actively Recruiting

8

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

9

University of Washington

Seattle, Washington, United States, 98195

Actively Recruiting

Loading map...

Research Team

R

Roni Wilke, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here